Genflow Biosciences PLC Announces AGM Notice
-
Park Jin-young Denies Cult Allegations Against Firstfruits Group
-
Writer Realizes She Is Lesbian After Child Comes Out as Transgender
-
MotorTrend's Top Electric Vehicle Picks for 2026
-
GTA 6 Advertising Strategy and Disc Version Controversy
-
St Francis School Leads €60,000 EU Project to Transform Early Childhood Education
-
IT’S TIME TO SHINE: ELEKTROS Thanks Its Shareholders and Looks Toward a Brighter Future in Critical Minerals and EV Technology
-
ELEKTROS Invites Shareholders to Shine Bright as the Holiday Season Nears, with Focus on Lithium, Critical Minerals and EV Innovation
-
As the Most Wonderful Time of the Year Approaches, ELEKTROS Celebrates Its Shareholders and Looks Ahead to a Bright Future
-
How to Find Joy in a Simpler, More Intentional Lifestyle
-
1986 Yugo GT with 121 Miles Listed for Sale on Bring a Trailer
-
Ukrainian MP Oleksiy Kucherenko Accidentally Exposes Himself During Live TV Interview
-
Malta Stuns Sweden with Late Penalty Comeback in Rugby Europe Trophy
Genflow Biosciences PLC Announces AGM Notice
LONDON, UNITED KINGDOM / ACCESS Newswire / May 22, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased to announce that it will hold its Annual General Meeting ("AGM") at 9am on Thursday 12 June 2025 at One Heddon Street, London, W1B 4BD.
The Notice of the AGM ("Notice") and 2025 Form of Proxy will shortly be available on the Company's website, www.genflowbio.com, and was, where applicable, posted to shareholders on 19 May 2025. Further details of the arrangements for this year's AGM are set out in the Notice.
As announced on 30 April 2025, the Company's Annual Report and Accounts for the year ended 31 December 2024 are also available on the website and has, where applicable, also been posted to registered shareholders.
Contacts
Genflow Biosciences | Harbor Access |
Dr Eric Leire, CEO | Jonathan Paterson, Investor Relations |
+32-477-495-881 | +1 475 477 9401 |
Brokers | |
Capital Plus Partners Ltd | |
Dominic Berger, +44 203 821 6167 | |
Jon Critchley, +44 0203 821 6168 |
About Genflow Biosciences
Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Scheduled to begin in 2025, Genflow's clinical trial aims to explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit www.genflowbio.com and follow the Company on LinkedIn and Twitter/X.
-Ends-
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
SOURCE: Genflow Biosciences PLC
View the original press release on ACCESS Newswire
B.Torres--AT
